Contribute Try STAT+ Today

Spare a thought for Illumina. The $56 billion dollar titan of genomics has become the world’s leading supplier of DNA sequencing technology. That’s been great for the company’s bottom line over the years. But Illumina’s market dominance is making it incredibly difficult to expand the business.

The latest example came this week when the Federal Trade Commission moved to block Illumina’s $7.1 billion merger with the cancer testing company Grail. Now Grail’s products are meant to detect cancer at the earliest stages when it’s most susceptible to treatment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • It’s important to keep an eye on the strategic advantages that companies are pursuing in order to achieve a monopoly in trade. In the case of healthcare genomics around the world, this may be extremely dangerous. The FTC’s fears are real, and their concerns are legitimate.

Comments are closed.